Comparative Pharmacology
Head-to-head clinical analysis: AYGESTIN versus GYNOREST.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AYGESTIN versus GYNOREST.
AYGESTIN vs GYNOREST
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Progestin that suppresses gonadotropin secretion, inhibits ovulation, and induces endometrial changes by binding to progesterone receptors.
Gynorest (dydrogesterone) is a synthetic progestogen that binds to the progesterone receptor with high selectivity, inducing conformational changes that promote transcription of progesterone-responsive genes. It has no androgenic, estrogenic, or corticosteroid activity, and does not inhibit ovulation.
5 mg orally once daily for secondary amenorrhea; 5 mg orally once daily from day 5 to day 25 of menstrual cycle for abnormal uterine bleeding.
100 mg orally twice daily for 5-10 days or 300 mg orally once daily for 6-12 days.
None Documented
None Documented
Terminal half-life 5-12 hours; clinical context: requires twice-daily dosing for consistent serum levels.
Terminal elimination half-life is approximately 16-20 hours; supports twice-daily dosing for maintenance of therapeutic levels.
Approximately 50-80% renal as metabolites, 10-20% fecal; less than 1% unchanged.
Renal: 50-80% as metabolites; Fecal: 20-50% as metabolites; Biliary excretion contributes to fecal elimination.
Category C
Category C
Progestin
Progestin